gressive acinar atrophy and dense lymphocytic infiltration. This is followed by dense fibrosis with few remaining acinar cells. The whole process may be complicated by secondary infection of the conjunctiva and subconjunctival contractures.
Treatment consists of the use of artificial tears, occlusion of the nasolacrimal duct to preserve what tears are present, mucolytic agents such as Nacetyl-cysteine, and general care of the eye to prevent and treat secondary infection.
Scleritis is a deep, penetrating inflammation of the scleral coat of the eye and must be distinguished from the more superficial episcleritis. The association of rheumatoid arthritis with scleritis is well established, whereas it seems very doubtful whether there is such an association with episcleritis (Jayson & Jones 1971) . Exacerbations of scleritis coincide not only with flares of arthritis, but also with extraarticular manifestations. Moreover, the pathology of rheumatoid scleritis resembles that of rheumatoid granulation tissue elsewhere. The symptoms of scleritis vary from the innocuous to severe pain and blurring ofvision. Such eyes must be examined by an ophthalmologist not only to determine the layers of blood vessels involved, but also to detect at an early stage corneal involvement, uveitis, retinitis and choroiditis. When scleritis heals, the scleral coat is left translucent so that the dark choroid is seen through it. Scleromalacia perforans is not a result of this scleral translucency, but may follow avascularity and infarction of areas of the sclera-necrotizing scleritis (Watson & Hayreh 1976) . This lesion appears as opaque white areas when advanced, but in the early stages avascular patches in the sclera can be detected by fluorescein angiography.
Virtually all patients with rheumatoid scleritis receive antiinflammatory drugs for their arthritis, so that it is difficult to assess the value of various forms of therapy on the scleritis. Oxyphenbutazone and indomethacin are probably as effective as steroids in their antiinflammatory action for scleritis. Steroids can be given locally as drops, by subcutaneous injection, or systemically. High doses are indicated if avascular patches are found. Penicillamine or immunosuppressive drugs may be necessary for very severe unremitting disease. also by a peculiar melting of corneal tissue (keratolysis). This is most common at the edge of the cornea (limbal guttering) but may also occur in the centre, and either lesion may proceed to corneal perforation. In contrast with scleritis, there may be little or no evidence of inflammation in the eye and the rheumatoid disease can be inactive and without extraarticular features. Reduced lacrimal secretion is found in most patients, although other evidence of the sicca syndrome is lacking (Jayson & Easty, in press ). Perhaps drying of the eyes, or deficiency of the a2 macroglobulin in tears that normally inhibits collagenase activity, predispose towards this lesion. Alternatively, small-vessel endarteritis round the periphery of the cornea may lead to ischmmic atrophy of corneal tissue.
The use of steroids in keratolysis is controversial, as they may hasten corneal melting. Collagenase inhibitors seem promising and in recurrent perforation there are anecdotal reports of healing on systemic immunosupressive and penicillamine therapy. Should perforation occur, then some form of graft repair is required, but these frequently melt away in the same way as the original cornea.
In juvenile chronic polyarthritis the two principal lesions are acute and chronic anterior uveitis (Smiley 1976) . The former usually occurs in the older male child with a peripheral lower-limb arthritis starting at about the age of 9 and with eye involvement starting at about 16 years. These children commonly develop sacroiliitis or frank ankylosing spondylitis, and a high proportion of them are of the tissue type HL-A B27. If treated promptly acute uveitis is readily brought under control with little or no permanent damage. Treatment consists of dilation of the pupil and local steroids.
Chronic anterior uveitis is more common in girls than boys, with an age of onset of arthritis of about 4 years, and of eye involvement of about 7 years. They more often have a mild seronegative monoor oligo-arthritis with positive tests for antinuclear factor (Schaller et al. 1974 ). The uveitis is often bilateral. As initial symptoms are often trivial and children ofthis age may not complain, it is essential that all children with chronic polyarthritis should be screened regularly by an ophthalmologist. In the early stages, there is little evidence of inflammation, with only inflammatory cells in the aqueous humour or as keratic precipitates, but pupillary abnormalities develop later. In advanced cases there may be complicated cataracts and corneal band opacities. Treatment is often difficult and prolonged; initially it involves dilation of the pupil and local steroids, but later it may require systemic steroid or other therapy. Despite treatment, chronic anterior uveitis nmay lead to severe visual damage.
In addition to all these hazards, which are direct complications of rheumatoid disease, the different types of antirheumatic treatment may themselves lead to ocular damage (Williamson 1976) . The principal problems are posterior subcapsular cataracts due to corticosteroids and retinopathy due to antimalarial drugs. There are many other less frequent or less significant ocular side-effects of these and other antirheumatic drugs.
Patients with ocular complications of rheumatoid arthritis are best assessed in a combined clinic by both the rheumatologist and ophthalmologist. Not only is this best for the patient; it also stimulates interdisciplinary ideas and understanding, for the common benefit of it.
